Tenofovir Disoproxil drug interactions | Litt's Drug Eruption and Reaction Database

Tenofovir Disoproxil comment watch save

TRADE NAMES: Atripla (Gilead); Complera (Gilead); Truvada (Gilead); Viread (Gilead)
INDICATIONS: HIV infection in combination with at least two other antiretroviral agents
CLASS: Antiretroviral, Covid-19 putative drug, Nucleoside analog reverse transcriptase inhibitor
HALF-LIFE: 12–18 hours

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Acyclovir, Adefovir, Atazanavir, Cidofovir, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil, Darunavir, Didanosine, Ganciclovir, High-fat foods, Indinavir, Ledipasvir & Sofosbuvir, Lopinavir, Protease inhibitors, Ritonavir, Telaprevir, Tipranavir, Trospium, Valacyclovir, Valganciclovir

See adverse reactions attributed to class:
Antiretroviral
Covid-19 putative drug
Nucleoside analog reverse transcriptase inhibitor

Investigated for treating COVID-19.

Atripla is tenofovir disoproxil, efavirenz and emtricitabine; Complera is tenofovir disoproxil, emtricitabine and rilpivirine; Truvada is tenofovir disoproxil and emtricitabine.

See also separate profile for tenofovir disoproxil in combination with cobicistat, elvitegravir and emtricitabine.

LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT EXACERBATION OF HEPATITIS

See full prescribing information for complete boxed warning.

Please login to view the rest of this drug profile.

DRUG REVIEW ARTICLE

DRUG REVIEW ARTICLE #2

Click on the DRUG REVIEW ARTICLE links (above) to see a review of tenofovir in the Taylor & Francis journal Expert Opinion on Drug Safety.

(Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 09/06/2023